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Abstract
Background: Malignant hypertension is a condition characterized by severe hypertension and multi-organ ischemic
complications. Albeit mortality and renal survival have improved with antihypertensive therapy, progression to
end-stage renal disease remains a significant cause of morbidity and mortality. The underlying cause of malignant
hypertension, which can be primary or secondary hypertension, is often difficult to identify and this can
substantially affect the treatment outcomes, as we report here.
Case presentation: A 33-year-old woman presented with severe hypertension and acute renal failure. Initial
evaluation demonstrated hyperreninemia with hyperaldosteronism and a possible renal artery stenosis at the
contrast-enhanced CT scan. Although this data suggested the presence of a secondary form of hypertension,
further exams excluded our first diagnosis of renal artery stenosis. Consequently, the patient did not undergo renal
angiography (and the contrast media infusion associated with it), but she continued to be medically treated to
achieve a tight blood pressure control. Our conservative approach was successful to induce renal function recovery
over 2 years of follow-up.
Conclusion: This case highlights the difficulty in differentiating between primary and secondary forms of malignant
hypertension, particularly when the patient presents with acute renal failure. Clinicians should consider renal artery
ultrasound as a first level diagnostic technique, given that the presentation of primary malignant hypertension can
often mimic a renal artery stenosis. Secondly, adequate control of blood pressure is essential for kidney function
recovery, although this may require a long time.
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Background
Malignant hypertension is a condition characterized by
severe hypertension and multi-organ ischemic complica-
tions [1]. Incidence of malignant hypertension has
remained stable over the years, although mortality and
renal survival have improved with the introduction of
antihypertensive therapy. However, progression to end-
stage renal disease remains a significant cause of mor-
bidity and mortality [2]. The underlying cause of malig-
nant hypertension can be primary or secondary
hypertension, and identification of the latter is
mandatory for choosing the correct treatment in order
to control blood pressure and improve end-organ
damage. However, correct diagnosis can be challenging
[3]. This case highlights the difficulty in differentiating
between primary and secondary hypertension, particu-
larly when the patient presents with acute renal failure.
Case presentation
A 33-year-old woman was referred to our Internal Medi-
cine Department by her GP after the recent diagnosis of
severe hypertension. While the diagnosis of hypertension
dated back to the day before, its onset was actually
unknown, as the patient had no memory of having ever
measured her blood pressure before, consistent with the
low awareness that young adults have of their hyperten-
sion [4]. During the visit she complained of fatigue.
Otherwise, her medical and family histories were unre-
markable. She used to smoke no more than 5 cigarettes
per day, did not take any prescription or over-the-counter
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medications and denied the use of recreational drugs, as
confirmed by the negativity of the urine drug screening.
On admission, her blood pressure was 240/140 mmHg,
but her other vital signs were normal and physical
examination was unremarkable. Initial laboratory studies
identified the presence of renal failure (creatinine
2.11 mg/dL), hypokalemia (potassium 2.45 mEq/L), and
anemia with thrombocytopenia (hemoglobin 10.6 g/dL,
a
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c
Fig. 1 a Abdomen CT scan image. The red arrow indicates the suspected left renal artery stenosis. b Renal echocolordoppler images and
velocimetric indices. PSV, peak systolic velocity; ACC, maximal systolic acceleration, AImax, maximal acceleration index; AT, acceleration time
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platelets 113.000/microm3), which were likely to be
hemolytic as LDH was elevated (572 U/L). There was also
an elevated CRP level of 170 mg/L. As for end-organ
damage, renal failure was associated with a proteinuria of
1.9 g over 24 h, while ultrasound revealed 2 normal-sized
kidneys with echogenic parenchyma. The ECG showed
signs of left ventricular hypertrophy, which was confirmed
by echocardiography, as the interventricular septum thick-
ness measured 19 mm and LV mass/BSA was 232 g/m2.
The left ventricular ejection fraction was 50 %, and there
was no aortic coarctation. Retinal examination revealed
grade III hypertensive retinopathy, showing the presence
of malignant hypertension, and antihypertensive drugs
were promptly administered.
Given that the clinical characteristics suggestive of
secondary causes of hypertension include early (i.e.
< 30 years) and sudden onset of hypertension in patients
without other risk factors, blood pressure levels higher
than 180/110 mmHg, and presence of target end-organ
damage [5], our next exams were aimed at excluding
secondary causes of hypertension. These analyses
showed that our patient had a hyperreninemia with a
secondary hyperaldosteronism (renin 266.4 microUI/mL,
aldosterone 38.1 ng/dL), which could be due to the pres-
ence of a renovascular disease, a renin-secreting tumor,
or a scleroderma renal crisis [6]. This last hypothesis
was however excluded by the absence of circulating
autoantibodies, as well as the absence of other clinical
and/or laboratory features suggestive of immunological
disorders. Moreover, a week after the start of the antihy-
pertensive therapy, not only CRP, but also hemoglobin,
platelets, and LDH normalized, so that we ruled out also
other conditions causing renal failure with thrombotic
microangiopathy and secondary hypertension, such as
the hemolytic uremic syndrome (HUS) and the throm-
botic thrombocytopenic purpura (PTT) [7].
Given the severity of the case, the diagnosis of any
underlying curable cause of the patient hypertension
could not be overlooked. At that stage, taking into ac-
count the laboratory exams, we needed to rule out sev-
eral possible causes of malignant hypertension, including
renal artery stenosis, and other insidious diseases such
as phaeocromocytomas [8], lymphomas, and other
renin-secreting masses [9]. For this reason, according to
current guidelines [10, 11], the patient underwent a con-
trast enhanced computed tomography (CT) of the abdo-
men. This exam did not show any suspicious masses.
Nevertheless, it visualized a stenotic left renal artery
(Fig. 1a), suggesting that our patient could have a fibro-
muscular dysplasia causing renal artery stenosis. Despite
most of our results were already strongly suggestive of
renal artery stenosis, before prescribing any angiography
with angioplasty, we requested a renal duplex ultrasound
exam. The analysis of blood flow velocity, which was
performed at the renal hilum as well as the intrapar-
enchymal arteries, showed a normal hemodynamic pat-
tern (Fig. 1b). Moreover, both proximal and distal
velocimetric indices were normal (Fig. 1c). In particular,
the maximal acceleration index, whose sensitivity is
93 % and specificity is 84 % [12], was greater than 9 s-1,
at all the sites. So, the renal duplex ultrasound did not
confirm -to our surprise- the suspected renal artery
stenosis.
Given this result, the renal angiography was put on
hold and the patient was treated with medical therapy
only, achieving blood pressure normalization over a few
weeks. Nevertheless, the persistence of the renal failure,
despite blood pressure normalization, led us to perform
a kidney biopsy in order to exclude primary renal dis-
eases. Kidney biopsy showed relative sparing of glom-
eruli with predominant vascular damage (Fig. 2). This
finding led us to the final diagnosis of malignant hyper-
tension complicating an underlying primary (essential)
hypertension with thrombotic microangiopathy.
a
b
Fig. 2 a-b Representative images of kidney biopsy pathology, where
vessel wall thickening with aspects of onionskin hyperplasia,
endothelial layer detachment, and intraluminal platelet thrombosis
with partial or complete obstruction of the vessel lumina can
be seen
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In this case antihypertensive therapy was able to
successfully reduce blood pressure and induce end-
organ damage recovery (Fig. 3). The echocardiography
showed that after 1 year from the start of the therapy
the interventricular septum thickness was of 11 mm, the
LV mass/BSA was of 61 g/m2, and that the ejection frac-
tion was of 74 %. The retinal examination did not show
any cotton wool spots or flame hemorrhages. Proteinuria
disappeared 4 months after hospitalization and renal
function progressively ameliorated over the following
2 years (Fig. 3), reflecting a slow recovery process that is
likely to include vascular remodeling [6].
Conclusions
This young woman’s presentation, marked by malignant
hypertension with renal failure, was a diagnostic chal-
lenge. On one hand, the clinical presentation, the hyper-
reninemia with a secondary hyperaldosteronism were
suggestive of a secondary form of hypertension, which at
the contrast-enhanced CT scan seemed to be that of a
renal artery stenosis. On the other hand, the renal du-
plex ultrasound exam was normal. Had there been a
renal artery stenosis, the angiography (with angioplasty)
might have been essential to successfully treat both
hypertension and renal failure. On the contrary, if this
had not been the case, unnecessary contrast media ad-
ministration could have prevented renal recovery. In the
end, we relied on the sensitivity [12] of the renal duplex
ultrasound exam and decided to avoid the angiography.
This case highlights the difficulty in differentiating
between primary and secondary hypertension in cases of
malignant hypertension. More than half of the cases of
malignant hypertension are in fact due to essential hyper-
tension [13]. Moreover, be it essential or secondary, the
clinical presentation of malignant hypertension can be the
same. In addition, if the clinical presentation does not help
discriminate, laboratory might not help either, in particu-
lar when it comes to the measurement of renin and aldos-
terone. Malignant hypertension is in fact typically
associated with an activation of the renin-angiotensin-
aldosterone system (RAAS) [14]. Although the exact
mechanism of malignant hypertension is unknown, sev-
eral studies have implicated the RAAS as a key factor to
its pathogenesis. The severe elevation of blood pressure
would in fact lead to RAAS activation through micro-
vascular damage and renovascular ischemia, and the in-
creased production of Angiotensin II would in turn
further increase blood pressure, leading to malignant
hypertension [14]. In this setting, it is not unusual to find
also other changes due to endothelial dysfunction [15],
which might explain the transient microangiopathic
hemolysis and increased CRP of our case.
Secondly, this case underlines the importance of
performing the renal artery duplex ultrasound as the
first-line (screening) exam when a renal artery stenosis is
suspected, before considering the renal angiography with
angioplasty, which is the reference standard for the ana-
tomic diagnosis and treatment of renal artery stenosis
a
b
Fig. 3 Mean arterial pressure and creatinine normalization. a antihypertensive therapy reduction. b over the 2-year follow-up
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[10]. Given that angiography is an invasive procedure
that carries a risk for serious complications, less invasive
techniques are advocated for the initial work-up of pa-
tients with suspected renal artery stenosis [12]. For this
reason, the European consensus on the diagnosis and
management of fibromuscular dysplasia suggests starting
the patient evaluation with renal duplex ultrasound and
then confirming the diagnosis with a CT-angiography
prior to angioplasty. As compared to computed tomog-
raphy, whose sensitivity has not always been found suffi-
cient to rule out a renovascular disease [16], the renal
duplex ultrasound exam, by the assessment of intrarenal
velocimetric indices, has a high sensitivity and a high
negative predictive value [12]. On the other hand, the re-
sults of the renal duplex ultrasound exam can be sub-
optimal if it is performed on obese patients, when apnea
is difficult or impossible, and where local expertise is
poor [10]. Nevertheless, in our case, given the patient’s
slender figure and compliance, as well as local expertise,
we took a step backward and decided to schedule a renal
duplex ultrasound before the angiography. Contrary to
the CT scan, the renal duplex ultrasound turned out to
be negative. Therefore, given that there had not been
technical biases hindering the diagnostic accuracy of the
exam, we based our next decision on the high sensitivity
and negative predictive value of the duplex ultrasound.
This helped avoid the angiography as well as the add-
itional contrast media administration that could have af-
fected negatively the renal recovery [17].
Despite the fact that over the last 40 years the in-
cidence of malignant hypertension has not changed
and remains 2-3/100,000/year, its prognosis has im-
proved significantly [13], which can be ascribed to
the introduction of modern antihypertensive drugs
and a better blood pressure control. Likewise, also
renal prognosis has improved, and the probability of
renal survival is 84 % and 72 % after 5 and 10 years
of follow-up, respectively [18]. In the end, our case
confirms that a tight control of blood pressure
during follow-up is one of the main predictors of
renal outcome in patients with malignant hyperten-
sion [18].
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